Black Diamond Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Black Diamond Therapeutics reported Q1 2026 cash, cash equivalents, and investments of $118.3 million, which is expected to fund operations into the second half of 2028. The company highlighted the dosing of the first patient in the Phase 2 trial of silevertinib in combination with temozolomide for newly diagnosed EGFRvIII+ GBM.
Key figures
- Revenue
- 0
- Net loss
- 9000000
- Ga expenses
- 4300000
- Rd expenses
- 7000000
- Cash position
- 118300000
- Net cash burn
- 10200000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.